These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 25693667)
1. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence. Fendler WP; Chalkidis RP; Ilhan H; Knösel T; Herrmann K; Issels RD; Bartenstein P; Cyran CC; Lindner LH; Hacker M Eur Radiol; 2015 Aug; 25(8):2214-21. PubMed ID: 25693667 [TBL] [Abstract][Full Text] [Related]
2. Multiparametric voxel-based analyses of standardized uptake values and apparent diffusion coefficients of soft-tissue tumours with a positron emission tomography/magnetic resonance system: Preliminary results. Sagiyama K; Watanabe Y; Kamei R; Hong S; Kawanami S; Matsumoto Y; Honda H Eur Radiol; 2017 Dec; 27(12):5024-5033. PubMed ID: 28639049 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631 [TBL] [Abstract][Full Text] [Related]
4. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565 [TBL] [Abstract][Full Text] [Related]
5. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review. Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981 [TBL] [Abstract][Full Text] [Related]
6. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study. Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of Kassem TW; Abdelaziz O; Emad-Eldin S Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778 [TBL] [Abstract][Full Text] [Related]
9. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449 [TBL] [Abstract][Full Text] [Related]
10. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127 [TBL] [Abstract][Full Text] [Related]
11. Lymph node standardized uptake values at pre-treatment Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776 [TBL] [Abstract][Full Text] [Related]
12. Prediction of Pathologic Grade and Prognosis in Mucoepidermoid Carcinoma of the Lung Using ¹⁸F-FDG PET/CT. Park B; Kim HK; Choi YS; Kim J; Zo JI; Choi JY; Shim YM Korean J Radiol; 2015; 16(4):929-35. PubMed ID: 26175595 [TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
14. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis. Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332 [TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET. Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730 [TBL] [Abstract][Full Text] [Related]
16. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363 [TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302 [TBL] [Abstract][Full Text] [Related]
18. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions. Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363 [TBL] [Abstract][Full Text] [Related]
19. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. Benz MR; Dry SM; Eilber FC; Allen-Auerbach MS; Tap WD; Elashoff D; Phelps ME; Czernin J J Nucl Med; 2010 Aug; 51(8):1174-81. PubMed ID: 20660389 [TBL] [Abstract][Full Text] [Related]
20. Predictive value of 2-deoxy-2-fluorine-18-fluoro-D-glucose positron emission tomography/computed tomography parameters for MYCN amplification in high-risk neuroblastoma. Li S; Liu J; Wang G; Feng L; Yang X; Kan Y; Wang W; Yang J Eur J Radiol; 2024 Jan; 170():111243. PubMed ID: 38043380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]